RxDoctor Payments Data

Ethan Greenberg, MD

Ophthalmology · Fridley, MNNPI 1225416944

Payments from drug & device makers

$1,113in general payments, 2019–2025

Across 20 payments — averaging $55.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$659
  • Sight Sciences, Inc.$171
  • Johnson & Johnson Surgical Vision, Inc.$104
  • Glaukos Corporation$52
  • AbbVie$50
  • The Cameron-ehlen Group, Inc.$40
  • plus $36 from 1 others

What the payments were for

  • Food & beverage$1,113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon11$659
Sight Sciences, Inc.2$171
Johnson & Johnson Surgical Vision, Inc.2$104
Glaukos Corporation2$52
AbbVie1$50
The Cameron-ehlen Group, Inc.1$40
Apellis Pharmaceuticals, Inc.1$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,113 in reported general payments places this provider in the 65th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$93,037
Medicare patients
259
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast33$24,016
Prednisolone Acetate234$11,810
RestasisCyclosporine18$11,369
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$4,336
Brimonidine Tartrate57$4,108
MoxifloxacinMoxifloxacin Hcl197$3,707
Ketorolac Tromethamine204$3,683
Latanoprost273$3,531
Travoprost14$1,916
Fluorometholone14$1,626
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat59$927
ValacyclovirValacyclovir Hcl12$584
Dorzolamide Hcl25$538
Dexamethasone Sodium Phosphate11$515
Timolol Maleate31$513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$50$11,36918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Fridley

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →